EMA Withdrawn: ATryn (antithrombin alfa) — Laboratoire Francais du Fractionnement et des Biotechnologies

View source ↗

Summary

The EMA withdrew ATryn (antithrombin alfa) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antithrombin Iii Deficiency

Drugs mentioned

• ATryn (recombinant human antithrombin)

Snippet

Status: Withdrawn. Therapeutic area: Antithrombin III Deficiency. MAH: Laboratoire Francais du Fractionnement et des Biotechnologies. Decision date: 22/12/2018